To include your compound in the COVID-19 Resource Center, submit it here.

Potiga ezogabine regulatory update

FDA approved an NDA from Valeant for Potiga ezogabine as an adjunctive treatment for partial onset seizures in adults. Valeant and partner GlaxoSmithKline expect to launch the product in the U.S. by year end. The

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE